Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase–producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.

Related collections

Author and article information

Journal

Title: Clinical Infectious Diseases

Publisher: Oxford University Press (OUP)

ISSN (Print): 1058-4838

ISSN (Electronic): 1537-6591

Publication date Created: September 17 2020

Publication date (Electronic): September 17 2020

Affiliations

[1 ]Infectious Diseases Azienda Ospedaliera Universitaria Pisana Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

[2 ]Department of Anaesthesia and Critical Care Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

[3 ]Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

[4 ]Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy

Article

DOI: 10.1093/cid/ciaa1410

PubMed ID: 32941593

SO-VID: 461bf19e-3263-4004-8398-39ecfdba2e57

License:

https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

History

Data availability:

Comments

Comment on this article

scite_

Cited by 58

See all cited by

- Version 1